Potential Role of Vitamin C Intracoronary Administration in Preventing Cardiac Injury After Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction
OBJECTIVE: The aim of the present study was to determine the effects of intravenous (IV) and intracoronary administration of Vitamin C on the incidence of periprocedural myocardial injury in patients undergoing primary percutaneous coronary intervention (PCI).
METHODS: In this prospective, double-blind, randomized clinical trial, that was conducted in Tehran Heart Center, Iran, between October 2016 and March 2017, 252 patients undergoing primary PCI were enrolled to receive either 3 g of IV Vitamin C before PCI and 100 mg of intracoronary Vitamin C during PCI in addition to the routine treatment (n = 126) or just the routine treatment (n = 126). Cardiac biomarkers were measured before and then 6 and 12 h postprocedurally. We determined the occurrence of contrast-induced acute kidney injury (CI-AKI), according to the levels of serum creatinine, neutrophil gelatinase-associated lipocalin, and platelet activation biomarker (P-selectin) in a subset of 119 patients before and 6 h after PCI.
FINDINGS: In the patients who received Vitamin C, the serum levels of troponin T after 12 h and creatine kinase-MB after 6 h were significantly lower than those in the placebo group (P = 0.003 andP = 0.00, respectively). CI-AKI occurred in 6 (4.7%) patients in the study group and 8 (6.3%) patients in the control group; there was no significant reduction in CI-AKI in the study group. In addition, the two groups were statically similar as regards the changes in the level of P-selectin.
CONCLUSION: In primary PCI patients, the prophylactic use of IV and intracoronary Vitamin C can confer additional clinical benefits such as cardioprotection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of research in pharmacy practice - 8(2019), 2 vom: 06. Apr., Seite 75-82 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shafaei-Bajestani, Negar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Contrast-induced acute kidney injury |
|---|
| Anmerkungen: |
Date Revised 09.04.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/jrpp.JRPP_18_78 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299790959 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299790959 | ||
| 003 | DE-627 | ||
| 005 | 20231225101118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jrpp.JRPP_18_78 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM299790959 | ||
| 035 | |a (NLM)31367642 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shafaei-Bajestani, Negar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential Role of Vitamin C Intracoronary Administration in Preventing Cardiac Injury After Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a OBJECTIVE: The aim of the present study was to determine the effects of intravenous (IV) and intracoronary administration of Vitamin C on the incidence of periprocedural myocardial injury in patients undergoing primary percutaneous coronary intervention (PCI) | ||
| 520 | |a METHODS: In this prospective, double-blind, randomized clinical trial, that was conducted in Tehran Heart Center, Iran, between October 2016 and March 2017, 252 patients undergoing primary PCI were enrolled to receive either 3 g of IV Vitamin C before PCI and 100 mg of intracoronary Vitamin C during PCI in addition to the routine treatment (n = 126) or just the routine treatment (n = 126). Cardiac biomarkers were measured before and then 6 and 12 h postprocedurally. We determined the occurrence of contrast-induced acute kidney injury (CI-AKI), according to the levels of serum creatinine, neutrophil gelatinase-associated lipocalin, and platelet activation biomarker (P-selectin) in a subset of 119 patients before and 6 h after PCI | ||
| 520 | |a FINDINGS: In the patients who received Vitamin C, the serum levels of troponin T after 12 h and creatine kinase-MB after 6 h were significantly lower than those in the placebo group (P = 0.003 andP = 0.00, respectively). CI-AKI occurred in 6 (4.7%) patients in the study group and 8 (6.3%) patients in the control group; there was no significant reduction in CI-AKI in the study group. In addition, the two groups were statically similar as regards the changes in the level of P-selectin | ||
| 520 | |a CONCLUSION: In primary PCI patients, the prophylactic use of IV and intracoronary Vitamin C can confer additional clinical benefits such as cardioprotection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Contrast-induced acute kidney injury | |
| 650 | 4 | |a Vitamin C | |
| 650 | 4 | |a creatine kinase-MB | |
| 650 | 4 | |a primary percutaneous coronary intervention | |
| 650 | 4 | |a troponin T | |
| 700 | 1 | |a Talasaz, Azita Hajhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Salarifar, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Pourhosseini, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Sadri, Farshad |e verfasserin |4 aut | |
| 700 | 1 | |a Jalali, Arash |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of research in pharmacy practice |d 2012 |g 8(2019), 2 vom: 06. Apr., Seite 75-82 |w (DE-627)NLM239778162 |x 2319-9644 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:2 |g day:06 |g month:04 |g pages:75-82 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jrpp.JRPP_18_78 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 2 |b 06 |c 04 |h 75-82 | ||